We’re delighted to announce that the Monash Organoid Symposium returns for its fifth edition on Thursday, November 20, 2025.
This methods-focused event continues to bring together researchers, industry partners, and students to explore the evolving landscape of organoid science.
While the program is still being finalised, we’re planning an exciting line-up of sessions that may cover topics such as immunity and infectious diseases, brain organoids, advanced 3D models, and the latest technologies shaping the field. For the second time, the Symposium will feature an exciting poster session, with awards and cash prizes for the most outstanding presentations.
Thanks to the generous support of our sponsors, this is a free event, open to all, and fully catered—with barista-made coffee to keep you energised throughout the day.
Following the success of our back-to-back events in 2024, we’re thrilled to continue the tradition. On Friday, November 21, the Functional High Throughput Technology Australia Nexus Symposium will follow, offering even more opportunities to engage with the local and interstate leaders in organoid research.
Stay tuned for the opening of registrations via Eventbrite and the announcement of our keynote speaker—we can’t wait to share more information with you soon!
For more information see the links below:
Another successful Organoid Symposium at Monash for this 2023 edition
Monash BDI Organoid Program Symposium 2022: A Resounding Success
Phenomics Australia provides a national centre of expertise and service provision to deploy a more comprehensive and sophisticated range of in vitro Genome Engineering and Disease Modelling capabilities to understand the functional consequences of DNA sequence variation in the human genome for health and disease while maintaining the expertise for in vivo disease modelling and genome engineering. To meet the high demand for adaptable and scalable disease-modelling platforms for improved diagnosis, Precision Medicine for genetic disorders, and therapeutic development by both academia and the biopharmaceutical industry, Phenomics Australia offers In Vitro services through a collaborative consortium of ten laboratories and facilities across Australia, operating at ANU (ANU Centre for Therapeutic Discovery), Perkins (Translational Cancer Research Program in Oncology), Monash (Monash Organoid Program & Monash Genome Modification Platform), MCRI (iPSC derivation & Gene Editing Facility), Peter Mac (Victorian Centre for Functional Genomics), UMelb (Centre for Stem Cell Systems & Stem Cell Disease Modelling Laboratory), UQ (In vitro Genome Engineering and Disease Modelling Service), and VCCRI (Stem Cell Production Facility iPSC Reprogramming Service)
